News

GTC and Lundbeck said that ATryn is approved for the prevention of peri-operative and peri-partum thromboembolic events in patients with hereditary antithrombin deficiency (HD AT), a rare and

Tekmira’s US-based affiliated office based in Washington state, Protiva, is expected to receive more than 15% of the estimated value of this award, as a subcontract. As per

Nabumetone product is bioequivalent and, therefore, therapeutically equivalent to Nabumetone tablets. Nabumetone belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs), which are used to reduce

Amorfix’ antibodies which showed efficacy in animal models of ALS will now be developed and prepared for clinical trials by Biogen Idec at its expense. As per the

CSL said that the main aim of the project is to create Victoria’s first large scale biotechnology facility for the late stage development of new therapies for cancer,

Watson andItero said that rFSH is currently in preclinical development as a biosimilar molecule for the treatment of female infertility. As per the terms of the agreement, Itero

Access Pharma and the biotechnology company are expected to develop the product with the use of its proprietary Cobalamin Oral Drug Delivery Technology, which utilises the body’s natural

Under the terms of the agreement, ValaMed will be involved in the development of chemo-sensitivity assays of cancerous tissues. The company is developing assessment methodologies that will allow

PharmaHub is expected to represent the Sichuan government in seeking out biotechnology projects and the STEC will be helping PharmaHub and its partners in executing business ventures in